Research programme: inflammation therapies - Potentia/ZyentiaAlternative Names: AggreSolve
Latest Information Update: 23 Nov 2014
At a glance
- Originator Potentia Pharmaceuticals; Zyentia
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 10 Jan 2007 Preclinical trials in Inflammation in USA (unspecified route)